Julian Adams, Ph.D., is president, research and development. Dr. Adams is responsible for the full spectrum of Infinity's drug discovery, preclinical and clinical development strategy, and regulatory affairs activities. Prior to joining Infinity in 2003, Dr. Adams was the senior vice president, drug discovery and development at Millennium Pharmaceuticals. In this capacity, he had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy. He joined Millennium through its acquisition of LeukoSite in 1999, where he was senior vice president research and development. Dr. Adams joined LeukoSite as a result of its acquisition of ProScript, Inc., where he had served as a member of the founding management team, executive vice president of research and development, and a member of the board of directors. Earlier in his career, Dr. Adams served in various positions, including director, medicinal chemistry at Boehringer Ingelheim, where he successfully discovered the drug Viramune® (nevirapine) for HIV. Also, from 1982-1987, he was a medicinal chemist at Merck.
Dr. Adams has received many awards, including the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation. Dr. Adams is an inventor of more than 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals. He is the editor of Proteasome Inhibition in Cancer Therapy, published in July 2004.
Dr. Adams received his B.S. from McGill University and his Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. He also received the degree of Doctor of Science, honoris causa, from McGill University in 2012.
Executive Vice President, Chief Financial Officer and Chief Business Officer
Lawrence E. Bloch, MD, JD is executive vice president, chief financial officer and chief business officer. Prior to joining Infinity in 2012, Dr. Bloch served as chief executive officer of NeurAxon, Inc., a company focused on developing next-generation pain therapeutics, from 2007 to 2011. Previously, he served as chief business officer and chief financial officer of NitroMed, Inc., raising $150 million in equity and $20 million in venture debt to support the commercial launch of BiDil®. From 1999 to 2004, he served as chief financial officer and vice president of business development, of Applied Molecular Evolution, Inc., leading the company’s $101 million initial public offering and $420 million merger with Eli Lilly and Company.
Dr. Bloch began his career as an emergency medicine resident physician at Massachusetts General Hospital and Brigham & Woman’s Hospital. He holds a J.D. from Harvard Law School, an M.D. from Harvard Medical School and an MBA from Harvard Business School.
James Ham is vice president, finance. He is responsible for the company’s financial planning/analysis and accounting groups. Prior to joining Infinity in 2013, Mr. Ham served as chief financial officer of Inotek Pharmaceuticals, a clinical-stage company focused on developing drugs for diseases of the eye, from 2008 to 2013. Previously, he worked at NitroMed from 2004 to 2008, where he was vice president of finance and chief financial officer, supporting the commercial launch of BiDil. Mr. Ham began his career at Bristol-Myers Squibb, where he spent 24 years holding increasingly senior positions in both the finance and business planning groups.
Mr. Ham received his MBA from St. John’s University and his B.S. in Business Administration from Villanova University.
John J. Keilty is vice president, information technology and informatics. Mr. Keilty is responsible for information systems, software development, structural biology, bioinformatics, and clinical informatics. Prior to joining Infinity in 2002, Mr. Keilty was an early member of Millennium Pharmaceuticals where he held various roles of increasing responsibility, including senior manager of molecular research services with broad ownership for the creation, management, implementation and transfer of much of the company’s core genomic technologies. Many of the developed software applications, algorithms and laboratory procedures were transferred to Millennium’s corporate partners as part of larger business collaborations. Before Millennium, Mr. Keilty worked in the Howard Hughes lab of Michael Green at the University of Massachusetts Medical Center, focusing on basic research in transcription and gene splicing.
Mr. Keilty received his B.A. in biology from Clark University and his M.S. in bioinformatics from Brandeis University.
Jeanette W. Kohlbrenner is vice president, human resources. She is responsible for Infinity’s human resource and organizational development functions. Ms. Kohlbrenner joined Infinity in 2006 with over 15 years of experience in senior human resource roles with life science and medical device companies, ranging from start-ups to fully commercial, global organizations. Prior to joining Infinity, Ms. Kohlbrenner was the business unit director of human resources for Cambrex Biosciences, where she was responsible for pharmaceutical development and manufacturing locations in the United States. Before Cambrex, Ms. Kohlbrenner worked at Syntonix Pharmaceuticals, where she served as director of human resources and a key member of the senior team working to build the company. Ms. Kohlbrenner also held human resource roles with Genetics Institute/Wyeth Pharmaceuticals and Hewlett-Packard’s Medical Device business (now Philips Medical). Early in her career, Ms. Kohlbrenner was a compensation and performance management consultant with William Mercer, a global leader in human resource consulting.
Ms. Kohlbrenner received her MBA from Babson College and her B.A. in mathematics from Holy Cross.
John J. Lee is vice president, pharmaceutical development. He is responsible for chemistry, manufacturing and control (CMC), analytical sciences, formulation sciences, and clinical supply and distribution for Infinity’s drug candidates. Prior to joining Infinity in 2001, Mr. Lee was a new product manager at Corning Life Science where he was responsible for developing new life science products from Corning research and technologies. Before Corning, Mr. Lee was an early member of Millennium Pharmaceuticals and played a key role in the successful positional cloning of the mouse obesity gene tubby before taking on various roles of increasing responsibility, including project lead for an ovarian cancer diagnostic program, a collaboration with Becton Dickenson, Mayo Clinic, and MD Anderson utilizing Millennium’s core genomic and proteomic technologies to develop a molecular screening test to detect early stage ovarian cancer. Prior to Millennium, Mr. Lee worked in the Developmental Chronobiology lab of Steven Reppert at Massachusetts General Hospital, where he focused on cloning G-protein coupled receptors and circadian biology.
Mr. Lee received his S.B. in Materials Science and Engineering from MIT.
Mr. McPherson joined Infinity at its inception and is responsible for managing the company’s expanding laboratories and office space, health and safety programs, and strategic sourcing activities. Prior to joining Infinity, Mr. McPherson had more than twenty years of laboratory and facility operations and management experience. Mr. McPherson previously held positions at Applied bioTechnology, Inc., ImmuLogic Pharmaceuticals, Inc. and Anadys Pharmaceuticals, where he planned and managed the laboratory operations and construction of the company’s laboratory/office/ manufacturing space and relocations.
Mr. McPherson received his B.S. in biochemistry from the University of Massachusetts in Amherst.
Vito J. Palombella, Ph.D., has served as Infinity’s chief scientific officer since 2010. He is responsible for the company’s drug discovery and preclinical development activities. Prior to his role as chief scientific officer, Dr. Palombella was vice president, biology and then vice president, drug discovery at Infinity. Prior to joining Infinity in 2004, Dr. Palombella served as director of molecular biology and protein chemistry at Syntonix Pharmaceuticals where he was responsible for improving and expanding its core Fc receptor-mediated drug delivery technology. Before joining Syntonix, Dr. Palombella served as senior director of cell and molecular biology at Millennium Pharmaceuticals, which he joined through its acquisition of LeukoSite in 1999. Prior to its acquisition by LeukoSite, Dr. Palombella held a number of positions at ProScript, Inc. While at ProScript, LeukoSite and Millennium, Dr. Palombella was involved in the discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy. He also managed a number of additional projects, including research into NF-KB regulation.
Dr. Palombella received his B.S. in microbiology from Rutgers University and his M.S. and Ph.D. in viral oncology and immunology from the New York University Medical Center working in the laboratory of Jan Vilček, M.D., Ph.D. He was also a post-doctoral fellow at Harvard University in the laboratory of Tom Maniatis, Ph.D.
Adelene Q. Perkins has served as Infinity's president and chief executive officer since 2009 and as board chair since 2012. Ms. Perkins first joined Infinity as chief business officer in 2002 and was named president in 2008. She has played an integral role in building the company, leading its transition from a platform to a product-based organization. She was the principal figure in structuring and restructuring Infinity's strategic relationships which have played a critical role in developing the company’s current product portfolio. Ms. Perkins has more than 25 years of international business experience in the biopharmaceutical industry, focused on building and leading high-caliber, cross-functional teams, corporate strategy, licensing and business development, strategic finance, and product life cycle management.
Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she was an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, she was vice president of emerging businesses and the cofounder and general manager of the DiscoverEaseT business unit at Genetics Institute, now part of Pfizer. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined GI from Bain & Company where she spent seven years providing strategic and operational advice to clients in the healthcare industry. Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is vice chair of the board of Project Hope and a member of the Villanova University College of Engineering Advisory Board.
James R. Porter, Ph.D., is senior director of product development at Infinity. As the product development leader of the company’s PI3K program, a position which he has held since July 2010, Dr. Porter is instrumental in the strategy and development of IPI-145, Infinity’s lead product candidate. Dr. Porter joined Infinity in 2002 and helped to build the company’s infrastructure, chemistry department, and pharmaceutical development group. In his tenure at Infinity, he has played an integral role in the company’s discovery and development initiatives.
Dr. Porter earned his B.A. in chemistry from the College of the Holy Cross and his Ph.D. in synthetic organic chemistry from Boston College.
David A. Roth, M.D. serves as chief medical officer at Infinity. In this role, he provides strategic leadership for Infinity’s clinical development activities, including responsibility for the company’s medical affairs, pharmacovigilance and clinical operations functions. Prior to joining Infinity in September 2013 as senior vice president of clinical development and medical affairs, Dr. Roth spent over ten years with Pfizer Inc. and Wyeth Pharmaceuticals where he contributed to the successful regulatory approval of several products, including Bosulif® (bosutinib), a dual Src/Abl tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia; Xyntha® and ReFacto AF® for the treatment of hemophilia A; and BeneFIX® for the treatment of hemophilia B. Dr. Roth also led the early development of palbociclib, a CDK 4/6 inhibitor, to Phase 3 evaluation in women with ER positive advanced breast cancer. Dr. Roth served in multiple leadership roles at Pfizer, where he was a vice president in the company’s oncology business unit. He joined Pfizer from Wyeth, where he held the role of assistant vice president, clinical research & development and global therapeutic area director of hematology. During his tenure at Pfizer and Wyeth, Dr. Roth also co-chaired Pfizer’s oncology research and development board and served on several oncology and hematology R&D leadership teams and governance committees. Prior to joining the pharmaceutical industry, Dr. Roth’s experience included over 10 years in research and clinical practice as an academic hematologist, and he had been on the full time faculty at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston.
Dr. Roth received his B.S. from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School in the Harvard-M.I.T. Division of Health Sciences and Technology.
Tamyra A. Toole, Esq., is vice president, regulatory affairs and quality assurance. She is responsible for the global regulatory strategy for the development of Infinity’s drug candidates, and the company’s compliance with regulatory standards and guidelines. Prior to joining Infinity in 2008, Ms. Toole held the role of senior director, regulatory affairs at NitroMed, Inc. and has previously held positions in regulatory affairs and quality assurance at Wyeth Pharmaceuticals, Millennium Pharmaceuticals and Organogenesis, Inc. She has experience developing drugs, biologics and medical devices in the oncology, hematology, cardiovascular, and plastic and reconstructive therapeutic areas. Prior to working in drug development, Ms. Toole held various positions in the Department of Nursing at Brigham and Women’s Hospital.
Ms. Toole received her J.D. from the Catholic University of America, Columbus School of Law and her B.S. in nursing from Villanova University.